AOD9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Pregnancy and breastfeeding === Although there are no major human studies of prednisolone use in pregnant women, studies in several animals show that it may cause birth defects including increased likelihood of cleft palate. Prednisolone is found in the breast milk of mothers taking prednisolone.
=== Post-classical === In medieval warfare, military feeding remained essentially the same as it had been in prior centuries. Armies typically had to acquire food supplies from the territory they were passing through. This meant that large-scale looting by soldiers was unavoidable, and was actively encouraged in the 14th century with its emphasis on chevauchée tactics, where mounted troops would burn and pillage enemy territory in order to distract and demoralize the enemy while denying them supplies. Through the medieval period, soldiers were responsible for supplying themselves, either through foraging, looting, or purchases. However, military commanders often provided their troops with food and supplies, but this would be provided instead of the soldiers' wages, or soldiers would be expected to pay for it from their wages, either at cost or even with a profit. During the Crusades, Crusaders carried foods such as dried meat and grain which could be used to make porridge and bought additional foods such as fruits, vegetables, and cheese locally. They also foraged and plundered for food. During the First Crusade, soldiers would have provided their own food, which could have meant mortgaging property or selling possessions to buy it. At the Siege of Antioch, the Crusaders' food supplies ran so low that a large force was sent away to forage and plunder food, opening the rest of the force up to a counterattack. At the subsequent Siege of Ma'arra, hunger among the Crusaders was so widespread that some resorted to cannibalism, feeding on the bodies of Muslims.
under the joint auspices of the George Washington University and the Carnegie Institution of Washington. There, the news on nuclear fission was spread even further, which fostered many more experimental demonstrations. The 6 January 1939 Hahn and Strassman paper announced the discovery of fission. In their second publication on nuclear fission in February 1939, Hahn and Strassmann used the term Uranspaltung (uranium fission) for the first time, and predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction. The 11 February 1939 paper by Meitner and Frisch compared the process to the division of a liquid drop and estimated the energy released at 200 MeV. The 1 September 1939 paper by Bohr and Wheeler used this liquid drop model to quantify fission details, including the energy released, estimated the cross section for neutron-induced fission, and deduced 235U was the major contributor to that cross section and slow-neutron fission.
Sources: en.wikipedia.org
Gary J. Patti is an American biochemist known for his research in metabolism and for using mass spectrometry to characterize biological processes. He is the Michael and Tana Powell Professor at Washington University in St. Louis. He is co-founder and Chief Scientific Officer of Panome Bio and an Associate Editor for Clinical & Translational Metabolism. Biemann Medal, 2024 ACS Midwest Award, 2023 Academy of Science Innovation Award, 2016 Edward Mallinckrodt Jr. Scholar Award, 2016 Pew Biomedical Scholars Award, 2015 Alfred P. Sloan Award, 2014 Camille Dreyfus Teacher-Scholar Award, 2014 Gary Patti publications indexed by Google Scholar
== Pharmacology == Midazolam is a short-acting benzodiazepine in adults with an elimination half-life of 1.5–2.5 hours. In the elderly, as well as young children and adolescents, the elimination half-life is longer. Midazolam is metabolised into an active metabolite alpha-hydroxymidazolam. Age-related deficits, renal and liver status affect the pharmacokinetic factors of midazolam as well as its active metabolite. However, the active metabolite of midazolam is minor and contributes to only 10% of biological activity of midazolam. Midazolam is poorly absorbed orally, with only 50% of the drug reaching the bloodstream. Midazolam is metabolised by cytochrome P450 (CYP) enzymes and by glucuronide conjugation. Oxidation of midazolam is the major metabolite in human liver microsome (HLM). The half-life (t1⁄2) of midazolam in HLM is 3.3 minutes. The therapeutic as well as adverse effects of midazolam are due to its effects on the GABAA receptors; midazolam does not activate GABAA receptors directly but, as with other benzodiazepines, it enhances the effect of the endogenous neurotransmitter GABA on the GABAA receptors (increasing the frequency of Cl− channel opening) resulting in neural inhibition. Almost all of the properties can be explained by the actions of benzodiazepines on GABAA receptors. This results in the following pharmacological properties being produced: sedation, induction of sleep, reduction in anxiety, anterograde amnesia, muscle relaxation and anticonvulsant effects.
Eventually, in the 1960s, it was recognised that lactose intolerance was correlated with race in the United States. Subsequent research revealed that lactose intolerance was more common globally than tolerance, and that the variation was due to genetic differences, not an adaptation to cultural practices.
=== Woodhouse Sixth Form College === Daisy Edgar-Jones, actress Johann Hari, journalist and writer Julia Hartley-Brewer, journalist, broadcaster and presenter Naomie Harris, actress David Hirsh, sociologist Jesse Honey, Mastermind winner 2010 and World Quiz Champion 2012 Michael McIntyre, stand-up comedian Ali Jawad, Paralympic powerlifter (silver medallist, Rio 2016) Robert Rinder, known as "Judge Rinder", barrister and television personality Stephen Bush, journalist Antigoni Buxton, Love Island participant and singer
Sources: en.wikipedia.org
The Quantum-Mechanical Calculation of the Resonance Energy of Benzene and Naphthalene and the Hydrocarbon Free Radicals" (PDF). The Journal of Chemical Physics. 1 (6): 362. Bibcode:1933JChPh...1..362P. doi:10.1063/1.1749304. Archived (PDF) from the original on 2022-10-09. —— (1935). "The Structure and Entropy of Ice and of Other Crystals with Some Randomness of Atomic Arrangement". Journal of the American Chemical Society. 57 (12): 2680–2684. Bibcode:1935JAChS..57.2680P. doi:10.1021/ja01315a102. —— (1940). "A Theory of the Structure and Process of Formation of Antibodies*". Journal of the American Chemical Society. 62 (10): 2643–2657. Bibcode:1940JAChS..62.2643P. doi:10.1021/ja01867a018. —— (1947). "Atomic Radii and Interatomic Distances in Metals". Journal of the American Chemical Society. 69 (3): 542–553. Bibcode:1947JAChS..69..542P. doi:10.1021/ja01195a024. ——; Itano, H. A.; Singer, S. J.; Wells, I. C. (1949). "Sickle Cell Anemia, a Molecular Disease". Science. 110 (2865): 543–548. Bibcode:1949Sci...110..543P. doi:10.1126/science.110.2865.543. PMID 15395398. S2CID 31674765. ——; Corey, R. B.; Branson, H. R. (1951). "The structure of proteins: Two hydrogen-bonded helical configurations of the polypeptide chain". Proceedings of the National Academy of Sciences. 37 (4): 205–11. Bibcode:1951PNAS...37..205P. doi:10.1073/pnas.37.4.205. PMC 1063337. PMID 14816373. —— (1964). "The Architecture of Molecules". Proceedings of the National Academy of Sciences. 51 (5): 977–984. Bibcode:1964PNAS...51..977P. doi:10.1073/pnas.51.5.977. ISSN 0027-8424. PMC 300194. PMID 16591181.
==== Israel ==== In October 2021, it was announced across Israeli media that 7-Eleven had signed a contract with Electra Consumer Products to open hundreds of stores in Israel. The first Israeli 7-Eleven location opened in January 2023 at Tel Aviv's Dizengoff Center. Under the agreement with 7-Eleven, Electra was to open a further approximately 400 branded stores in Israel, 300 of them through franchisees. Ultimately the effort failed, and the stores were sold in May 2024.
This is a list of instant foods. Instant foods are convenience foods which require minimal preparation, typically just adding water or milk. Some authors define "instant" food as requiring less than five minutes of preparation and "ultra-instant food" as requiring less than one minute. Instant foods are often dehydrated, freeze-dried, or condensed.
== Research directions == Key research questions in PMOS focus on the best way to manage the condition, including with new anti-obesity drugs. In terms of criteria for diagnosis, age-specific levels of AMH need to be specified. Biomarkers are needed for early diagnosis and to guide drug development. Another open question is how to define the male phenotype to assess male relatives of women with PMOS. Research is exploring better ways to assess and predict metabolic complications. Current clinical tests for insulin resistance lack accuracy and standardisation, and the gold-standard method is impractical in clinical settings. Emerging approaches include multiomics, which may uncover biomarkers for diagnosis and subtyping, and artificial intelligence (AI)-based methods, which can identify patterns in medical data and also classify patients into subgroups. Combining AI with omics might improve early diagnosis, risk prediction, personalised treatment, and long-term monitoring, though robust validation in large, diverse cohorts remains necessary. As of 2024, studies have successfully developed in vitro PMOS disease models through human embryonic stem cells (hESCs) and induced pluripotent stem cell technology (iPSC). Both can be derived from individuals with PMOS and can differentiate into various cell types. Using adult somatic cells, iPSCs can reprogram the cells into a pluripotent state, which can then be specified to replicate PMOS-like traits.
Kayser–Fleischer rings, a rusty brown discoloration at the outer rims of the iris due to copper deposition noted in 90% of patients, become evident as copper begins to accumulate and affect the nervous system. Almost always, death occurs if the disease is untreated. Fortunately, identification of the mutations in the Wilson ATPase gene underlying most cases of Wilson's disease has made DNA testing for diagnosis possible. If diagnosed and treated early enough, patients with Wilson's disease may live long and productive lives. Wilson's disease is managed by copper chelation therapy with D-penicillamine (which picks up and binds copper and enables patients to excrete excess copper accumulated in the liver), therapy with zinc sulfate or zinc acetate, and restrictive dietary metal intake, such as the elimination of chocolate, oysters, and mushrooms. Zinc therapy is now the treatment of choice. Zinc produces a mucosal block by inducing metallothionein, which binds copper in mucosal cells until they slough off and are eliminated in the feces. and it competes with copper for absorption in the intestine by DMT1 (Divalent Metal transporter 1). More recently, experimental treatments with tetrathiomolybdate showed promising results. Tetrathiomolybdate appears to be an excellent form of initial treatment in patients who have neurologic symptoms. In contrast to penicillamine therapy, initial treatment with tetrathiomolybdate rarely allows further, often irreversible, neurologic deterioration.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.